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Background. Obesity has become an epidemic problem, con-
tributing to metabolic syndrome, type 2 diabetes, hypertension,
and cardiovascular disease. An adequate blood pressure con-
trol in this population of obese individuals is extremely difficult
to achieve, and in most cases, therapeutic combinations are re-
quired. Pharmacologic treatment with moxonidine, a central I1
imidazole receptor agonist, is a very interesting option because
it acts upon the mechanisms implicated in the development of
arterial hypertension in these patients. In addition, the drug im-
proves the peripheral insulin resistance often found in obese
patents, which contributes to maintain high blood pressure.
Methods. An interventional study has been designed, adding
moxonidine to noncontrolled hypertensive, obese subjects in
whom a hypocaloric diet was previously recommended. A total
of 25 primary care centers participated in the study, with a total
of 135 patients recruited.
Results. One hundred twelve patients were included in the
study; 25 of them had type 2 diabetes. The mean reduction in
systolic and diastolic blood pressure after 6 months treatment
with moxonidine was 23.0 and 12.9 mm Hg, respectively. The
mean systolic and diastolic pressures were 158.5 ± 10.6 and
95.1 ± 9 mm Hg, respectively, at baseline, versus 135.5 ± 11.6
and 82.2 ± 5.8 mm Hg at the end of the study. Creatinine
clearance was significantly decreased in hyperfiltrating obese
patients (143.6 ± 31 vs. 128.2 ± 27.9, P < 0.0001), without
any significant change in patients with normal or slightly de-
creased renal function (81.9 ± 18.9 vs. 80.9 ± 17.5). Only 8
mild adverse reactions in 7 patients were recorded during the
study.
Conclusion. Moxonidine is useful and safe for controlling
arterial hypertension in obese patients.
Obesity shows an increased cardiovascular risk be-
cause it is associated with the development of type 2
diabetes and dyslipidemia [1, 2]. Of the different anthro-
pomorphic types of obesity, the android presentation is
the most deleterious one, from the cardiovascular view.
This type of obesity is characterized by increased visceral
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fat, with a waist/hip index above 0.95 and 0.85 in males
and females, respectively. Obesity increases both cardio-
vascular morbidity-mortality and health care costs. It has
been estimated that an increase of 1 kg in body weight
implies a 3.1% rise in global cardiovascular risk.
An increase in body mass index (BMI) is correlated
to increased insulin resistance. In fact, increased body
weight (BW) is a risk factor for the development of
type 2 diabetes [3–5]. The association of obesity, di-
abetes, and hypertension is highly prevalent, and in-
creases with age. Epidemiologic studies indicate that after
50 years of age, this triple association is relatively fre-
quent. These processes are, in turn, characterized by
underlying hyperinsulinism and resistance to the pe-
ripheral action of insulin—this constituting a common
etiopathogenic factor that facilitates the expression of
these associated pathologic processes.
Obesity alters renal function in addition to causing
hypertension [6, 7]. Among the different mechanisms
implicated should be mentioned the insulin resistance
and hyperinsulinism generated, activation of the renin-
angiotensin system and sympathetic nervous system, as
well as intrarenal alterations. Different evidence has
shown that blocking the renin-angiotensin-aldosterone
system is a benefit for this obese hypertensive popula-
tion, similar to the selective alpha- and beta-adrenergic
block. Numerous studies have analyzed the role of lep-
tin in the activation of the sympathetic nervous system
in such individuals. It is known that obesity favors an
increase in intraglomerular pressure, resulting in hyper-
filtration, glomerular damage, sodium retention, and in-
creased arterial pressure.
Of the different factors that associate arterial hyper-
tension and obesity, peripheral insulin resistance and hy-
perinsulinism, which are often found in obesity, should
be mentioned. It has been suggested that insulin resis-
tance and hyperinsulinism constitute the etiopathogenic
link between obesity and arterial hypertension. Both
of these factors favor metabolic alterations, which in
turn increase cardiovascular risk. From the pathogenic
S-20
Abella´n et al: Efficacy of moxonidine in obese, noncontrolled hypertensive patients S-21
perspective, and in addition to the above factors, the de-
velopment of hypertension in obese patients seems to be
mediated by other mechanisms that alter renal function—
with chronic increments in tubular sodium reabsorption
and displacement of the natriuresis/pressure curve, in-
creased sympathetic and renin-angiotensin system activ-
ity, among other phenomena.
Pharmacologic treatment with moxonidine, a central
I1 imidazole receptor agonist, is a very interesting option
because it acts upon the mechanisms implicated in the
development of arterial hypertension in these patients [1,
2, 8]. In addition, the drug improves the peripheral insulin
resistance often found in obese patents, which contributes
to maintain high blood pressure [9, 10].
METHODS
An open, multicenter observational study was de-
signed in the primary care setting to assess the effects of
moxonidine on a subset of obese and hypertensive indi-
viduals not adequately controlled with their standard an-
tihypertensive treatment. An evaluation was performed,
analyzing the blood pressure control achieved after the
association of moxonidine to their previous treatment. At
the end of the study, patients were considered as BP con-
trolled if BP was <140/90 mm Hg in nondiabetic patients
and <130/85 mm Hg in diabetics [12]. The tolerance of the
drug and the possible repercussions upon renal function
were also analyzed.
The study included obese hypertensive patients aged
18 to 80 years who gave informed consent to participation
and met the following inclusion criteria: (1) prior treat-
ment with antihypertensive medication, although without
adequate control [systolic blood pressure (SBP) 140–
179 mm Hg and/or diastolic blood pressure (DBP) 90–
109 mm Hg]. In the case of diabetic hypertensive individ-
uals previously treated with antihypertensive drugs, the
requirements were SBP 130 to 179 mm Hg and/or DBP 85
to 109 mm Hg; and (2) overweight-obese status as defined
by BMI ≥27.5 and <40.
The following exclusion criteria were established: sec-
ondary hypertension, acute myocardial infarction in the
previous 6 months, arrhythmias, unstable angina, heart
failure (left ventricle ejection fraction <40%), cere-
brovascular events in the preceding year, liver failure
(hepatic transaminase levels more than 2-fold the base-
line values), women of fertile age failing to adopt ade-
quate contraceptive measures, and bedridden patients or
individuals with incapacitating illnesses.
Blood pressure was measured according to internation-
ally accepted guidelines [11, 12]. Blood pressure was de-
termined in the dominant arm of the patient, in the sitting
position, and after a 5-minute rest period, early in the
morning. Three valid recordings were obtained spaced at
least 3 minutes apart. The pressure value corresponding
to the visit was taken to be the arithmetic mean of the
SBP and DBP values. The patients were weighed, and
body height was measured without shoes and wearing
only light clothing. The BMI was also calculated [weight
in kg/(height in m)2].
In all cases, moxonidine 0.4 mg was added to the ha-
bitual antihypertensive medication to control blood pres-
sure. The drug was administered early in the morning for
6 months, and a hypocaloric (1200 calorie) diet was pre-
scribed together with regular daily exercise (walking for
half an hour). Monthly clinical controls were carried out.
Two biochemical controls were done: one before the
active treatment period, and the second at the end of
the study—including the evaluation of renal function.
Glomerular filtration rate (GFR) was assessed by the
Cockroft and Gault formula. Patients who had GFR
higher than 125 mL/min in men, and higher than 100 mL/
min in women were classified as hyperfiltrating. Safety
was evaluated by recording the adverse reactions either
spontaneously reported by the patient or detected by
the investigator, and which appeared or worsened in the
course of the study. Safety was also assessed according to
evolution of the laboratory test parameters.
A clinical database (Microsoft Excel 97; Microsoft,
Redmond, WA, USA) was established for the statisti-
cal study, with internal coherence rules and ranges to
detect incorrections in the data tables. The SPSS ver-
sion 11 statistical package was used (Chicago, IL, USA).
The continuous variables were described employing cen-
tral tendency (mean, median) and dispersion measures
(standard deviation, minimum, and maximum). The cat-
egorical variables were described based on absolute and
relative frequency tables. The contrasts and statistical
tests employed accepted significance for P < 0.05.
RESULTS
The results obtained were divided into 4 sections:
sample characteristics, antihypertensive efficacy analysis,
study of renal function, and safety analysis.
Sample characteristics
A total of 112 patients from 135 recruited were finally
included in the study (61 males and 51 females), aged
61.2 ± 10.6 years, with a height of 161.6 ± 8.6 cm.
Twenty-five of them had type 2 diabetes. Body weight de-
creased from 88.19 ± 12.09 kg (baseline) to 84.9 ± 11.5 kg
(6-month) (P < 0.01). BMI decreased from 33.6 ±
3.3 kg/m2 (baseline) to 32.3 ± 3.2 kg/m2 (6-month) (P <
0.01). Baseline waist perimeter was: 111.7 ± 14.1 cm, hip
perimeter: 110.3 ± 13.3 cm, and waist/hip index: 1.0 ± 0.1.
The cardiovascular risk factor anamnesis iden-
tified hypercholesterolemia in 47.7% of patients,
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Fig. 1. Blood pressure evolution after moxonidine treatment. ∗SBP
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Fig. 2. Percentage of patients that achieved BP control along the
study period, comparing diabetics (<130/85 mm Hg) and nondiabet-
ics (<140/90 mm Hg).
hypertriglyceridemia in 17.4%, diabetes in 22.3%, and
tobacco smoking in 27.5%.
Antihypertensive efficacy analysis
Because the patients were both obese and hyperten-
sive, a first evaluation will focus on the evolution of blood
pressure. The mean decrease in SBP after moxonidine
treatment and during the 6-month duration of the study
was 23.01 mm Hg (14% of the baseline value). The de-
crease in DBP was 12.9 mm Hg (13.5% of the baseline
value). For the whole group, the mean systolic and dias-
tolic pressures were 158.5 ± 10.6 and 95.1 ± 9 mm Hg,
respectively, at baseline, versus 135.5 ± 11.6 and 82.2 ±
5.8 mm Hg at the end of the study (Fig. 1). Comparing
diabetics and nondiabetics, the mean blood pressure re-
duction at the end of the study was significantly more
marked in the group of nondiabetic (159 ± 12/95 ± 10 vs.
135 ± 10/82 ± 6) than diabetic patients (157 ± 11/95 ± 7
vs. 137.6 ± 12/83 ± 6), P < 0.01.
In terms of blood pressure control, 96 patients (86%)
achieved diastolic BP control at the end of the study; 70
(63%) of them had systolic BP adequately controlled, and
54 (48%) were seen to have adequately controlled the 2
BP components after 6 months. A significantly greater
percentage of patients who achieved blood pressure con-
trol was found among nondiabetics compared with dia-
betic patients (57% vs. 18%, P < 0.001) (Fig. 2), although
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Fig. 3. Evolution of body mass index (BMI) during the study. Baseline
BMI vs. final BMI. P < 0.01.
the BP control goal demanded by diabetics was more
strict (<130/85 mm Hg), than in nondiabetics (140/90 mm
Hg). The BMI was also seen to decrease from 33.6 to 32.3
kg/m2 (P< 0.01) (Fig. 3).
Associated factors for controlling blood pressure are
expressed in Table 1. Only lower baseline glucose lev-
els are significantly related to blood pressure control, ex-
pressing that diabetic patients had worse BP control, but
the percentage of reduction of the BMI was not signifi-
cantly related to BP control (Table 1).
The evolution of biochemical parameters is shown in
Table 2.
Study of renal function
The mean initial and final plasma creatinine levels did
not vary (0.96 ± 0.2), but comparing the group of 23 hy-
perfiltrating patients (GFR >125 mL/min in men and
>100 mL/min in women) with those with baseline nor-
mal renal function resulted in the following: hyperfiltrat-
ing patients had a significantly lower mean plasma crea-
tinine value (0.81 ± 0.2 vs. 1.01 ± 1.8 mg/dL, P < 0.001),
which increased at the end of the study to 0.85 ± 0.2
mg/dL. Plasma creatinine did not change over the study
in obese patients with normal renal function (1.01 ± 1.8
vs. 0.99 ± 1.9 mg/dL). At the same time, creatinine clear-
ance (Cockcroft-Gault formula) significantly decreased
in the whole group (97.3 ± 35.2 to 92.8 ± 30.1, P < 0.001)
after 6 months of treatment. However, comparing the 2
groups of patients in relation to GFR, this decrement
in the mean GFR was only significant in the group of
hyperfiltrating obese patients (N = 23) (143.6 ± 31 vs.
128.2 ± 27.9, P < 0.0001), without any significant change
in those obese patients with normal or slightly decreased
renal function (81.9 ± 18.9 vs. 80.9 ± 17.5), although
hyperfiltrating patients were more obese (98.8 ± 14 vs.
85.1 ± 11 kg, P < 0.001). The percent of reduction in body
weight at the end of the study was not significantly differ-
ent between hyperfiltrating and nonhyperfiltrating obese
patients (3.7% vs. 3.3% BW reduction, respectively).
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Table 1. Associated factors in relation to BP control
Noncontrolled Controlled Total
Mean SD Mean SD Mean SD P valuea
Age years 61.69 10.97 60.14 9.99 61.28 10.69 0.4357
Body weight baseline kg 88.81 12.82 86.45 9.77 88.19 12.09 0.3664
BMI baseline kg/m2 33.67 3.42 33.35 2.82 33.59 3.26 0.6171
BMI reduction at 6 months % 3.32 3.63 4.26 2.49 3.58 3.36 0.0908
Glucose baseline mg/dL 123.16 35.73 106.3 24.99 110.85 29.09 0.0403
Glucose 6 months mg/dL 112.53 19.38 99.4 28.60 103.17 23.04 0.0799
aMann-Whitney U test.
Table 2. Biochemical data at baseline and at the end of the study
Mean Median SD Min. Max. P valuea
Glucose baseline mg/dL 109.48 101.00 27.67 70.00 215.00 0.0001
Glucose 6 months mg/dL 103.17 99.00 23.04 68.00 187.00
Cholesterol baseline mg/dL 225.49 223.00 36.63 130.00 305.00 <0.0001
Cholesterol 6 months mg/dL 210.14 207.50 25.58 151.00 293.00
Triglycerides baseline mg/dL 159.77 145.50 75.92 32.00 459.00 0.0016
Triglycerides 6 months mg/dL 147.62 136.50 88.09 47.00 842.00
HDL-cholesterol baseline mg/dL 50.22 48.00 11.60 28.40 90.00 0.1093
HDL-cholesterol 6 months mg/dL 50.72 48.00 10.33 31.60 77.00
Creatinine baseline mg/dL 0.96 0.93 0.20 0.50 1.87 0.5053
Creatinine 6 months mg/dL 0.96 0.90 0.19 0.60 1.82
aWilcoxon test.
Safety analysis
Only 8 adverse reactions were recorded in 7 patients
[knee pain, dizziness, drowsiness (3 cases), dry mouth,
and slight worsening of chronic obstructive lung disease.
DISCUSSION
The present study demonstrates the efficacy of mox-
onidine for the control of arterial hypertension associated
with obesity, even in diabetic patients. An adequate blood
pressure control in this population of obese individuals,
particularly diabetics, is extremely difficult to achieve,
and in most cases therapeutic combinations are required.
The special mechanism of action of moxonidine [13–16],
reducing sympathetic activity [17–19] and improving in-
sulin sensitivity [20], may account for the increased an-
tihypertensive efficacy in this population [21–23]. Thus,
moxonidine is particularly useful in cases of arterial hy-
pertension associated with metabolic syndromes [24–30].
On the other hand, the results obtained in this study
indicate that hyperfiltrating patients, as a result of
hypocaloric diet plus moxonidine treatment and BP con-
trol, have decreased glomerular filtration rate (GFR)
to near normal values, but GFR is not altered in those
patients with normal or slightly reduced GFR [31–36].
These changes seen in creatinine clearance could also
be explained at least in part by the reduction of body
weight. GFR was estimated by the Cockroft-Gault for-
mula; however, the body weight reduction was similar in
both groups of high and normal GFR.
As a comparison of our results with those of other
authors, Haenni et al [3] investigated whether insulin
sensitivity and response are modified by moxonidine
treatment in obese patients with primary arterial hy-
pertension. They analyzed 74 hypertensive subjects with
BMI >27, and found a 21% increase in insulin sensitivity
versus the placebo group. Moreover, no significant side
effects were observed. Ernsberger et al [37] also analyzed
the influence of moxonidine-induced sympathetic inhibi-
tion upon carbohydrate metabolism in genetically obese
and hypertensive rats—recording a 71% decrease in hy-
perinsulinemia, and a 25% reduction of free fatty acids.
On the other hand, expression of the beta-subunit of the
insulin receptor was seen to increase 19%. Rosen et al [38]
concluded that moxonidine action upon the imidazole
receptors reduces sympathetic activity and offers bene-
ficial effects at different levels, including blood pressure,
insulin resistance, lipid metabolism, and others. Regard-
ing kidney function, Wiecek et al [39] found moxonidine
to exert beneficial effects upon the urinary excretion of
electrolytes and on renal hemodynamics.
Another important consideration is the safety of the
drug because few significant side effects were recorded in
our study, which is in agreement with the observations of
other authors. In effect, moxonidine is very well tolerated,
with few interactions when combined with other drugs.
CONCLUSION
The present study shows that moxonidine asso-
ciated with hypocaloric diet added to the habitual
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antihypertensive regimen is useful and safe for control-
ling arterial hypertension in obese patients. This anti-
hypertensive regimen corrects hyperfiltration in obese
hyperfiltrating patients, but does not produce any changes
in renal function in obese hypertensive patients with nor-
mal or slightly reduced GFR. Thus, moxonidine should
be taken into consideration when treating obese patients
with plurimetabolic syndromes.
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